These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27599161)

  • 1. Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.
    Decock A; Ongenaert M; De Wilde B; Brichard B; Noguera R; Speleman F; Vandesompele J
    Epigenetics; 2016 Oct; 11(10):761-771. PubMed ID: 27599161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.
    Bénard J; Raguénez G; Kauffmann A; Valent A; Ripoche H; Joulin V; Job B; Danglot G; Cantais S; Robert T; Terrier-Lacombe MJ; Chassevent A; Koscielny S; Fischer M; Berthold F; Lipinski M; Tursz T; Dessen P; Lazar V; Valteau-Couanet D
    Mol Oncol; 2008 Oct; 2(3):261-71. PubMed ID: 19383347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis with machine learning identifies diagnostic and prognostic signatures in neuroblastoma based on differentially DNA methylated enhancers between INSS stage 4 and 4S neuroblastoma.
    Li S; Mi T; Jin L; Liu Y; Zhang Z; Wang J; Wu X; Ren C; Wang Z; Kong X; Liu J; Luo J; He D
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):148. PubMed ID: 38512513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing.
    Decock A; Ongenaert M; Van Criekinge W; Speleman F; Vandesompele J
    Sci Data; 2016 Feb; 3():160004. PubMed ID: 26836295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.
    Lavarino C; Cheung NK; Garcia I; Domenech G; de Torres C; Alaminos M; Rios J; Gerald WL; Kushner B; LaQuaglia M; Mora J
    BMC Cancer; 2009 Feb; 9():44. PubMed ID: 19192278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
    Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
    J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation of tumor-suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors.
    Michalowski MB; de Fraipont F; Plantaz D; Michelland S; Combaret V; Favrot MC
    Pediatr Blood Cancer; 2008 Jan; 50(1):29-32. PubMed ID: 17570703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Over-Expression of E2F3 Might Serve as Prognostic Marker for Neuroblastoma Patients with Stage 4S Disease.
    Parodi S; Ognibene M; Haupt R; Pezzolo A
    Diagnostics (Basel); 2020 May; 10(5):. PubMed ID: 32429447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Analysis Made It Possible to Identify Gene-Driver Alterations Covering the Time Window between Diagnosis of Neuroblastoma 4S and the Progression to Stage 4.
    Ognibene M; De Marco P; Parodi S; Meli M; Di Cataldo A; Zara F; Pezzolo A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.
    Decock A; Ongenaert M; Cannoodt R; Verniers K; De Wilde B; Laureys G; Van Roy N; Berbegall AP; Bienertova-Vasku J; Bown N; Clément N; Combaret V; Haber M; Hoyoux C; Murray J; Noguera R; Pierron G; Schleiermacher G; Schulte JH; Stallings RL; Tweddle DA; ; De Preter K; Speleman F; Vandesompele J
    Oncotarget; 2016 Jan; 7(2):1960-72. PubMed ID: 26646589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias.
    Nair SS; Coolen MW; Stirzaker C; Song JZ; Statham AL; Strbenac D; Robinson MD; Clark SJ
    Epigenetics; 2011 Jan; 6(1):34-44. PubMed ID: 20818161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas.
    Tang XX; Evans AE; Zhao H; Cnaan A; London W; Cohn SL; Brodeur GM; Ikegaki N
    Clin Cancer Res; 1999 Jun; 5(6):1491-6. PubMed ID: 10389937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspase-8 gene expression in neuroblastoma.
    Casciano I; Banelli B; Croce M; De Ambrosis A; di Vinci A; Gelvi I; Pagnan G; Brignole C; Allemanni G; Ferrini S; Ponzoni M; Romani M
    Ann N Y Acad Sci; 2004 Dec; 1028():157-67. PubMed ID: 15650242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term hepatic outcomes in survivors of stage 4S and 4 neuroblastoma in infancy.
    French AE; Irwin MS; Navarro OM; Greenberg M; Nathan PC
    Pediatr Blood Cancer; 2012 Feb; 58(2):283-8. PubMed ID: 21370436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of TrkA protein detection by monoclonal antibody 5C3 in neuroblastoma.
    Kramer K; Gerald W; LeSauteur L; Uri Saragovi H; Cheung NK
    Clin Cancer Res; 1996 Aug; 2(8):1361-7. PubMed ID: 9816308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the prognosis of stage 4s neuroblastoma in patients 12 months of age and older really excellent?
    Iehara T; Hiyama E; Tajiri T; Yoneda A; Hamazaki M; Fukuzawa M; Hosoi H; Sugimoto T; Sawada T
    Eur J Cancer; 2012 Jul; 48(11):1707-12. PubMed ID: 22305511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
    Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL.
    Subhash S; Andersson PO; Kosalai ST; Kanduri C; Kanduri M
    Clin Epigenetics; 2016; 8():106. PubMed ID: 27777635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.